Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
 

Learn about the flu shot, COVID-19 vaccine, and our masking policy »

Stanford Health Care

Assessment: Botulinum neurotoxin for the treatment of spasticity (an evidence-based review) - Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology NEUROLOGY Simpson, D. M., Gracies, J., Graham, H. K., Miyasaki, J. M., NAUMANN, M., Russman, B., Simpson, L. L., So, Y. 2008; 70 (19): 1691-1698

Abstract

To perform an evidence-based review of the safety and efficacy of botulinum neurotoxin (BoNT) in the treatment of adult and childhood spasticity.A literature search was performed including MEDLINE and Current Contents for therapeutic articles relevant to BoNT and spasticity. Authors reviewed, abstracted, and classified articles based on American Academy of Neurology criteria (Class I-IV).The highest quality literature available for the respective indications was as follows: adult spasticity (14 Class I studies); spastic equinus and adductor spasticity in pediatric cerebral palsy (six Class I studies).Botulinum neurotoxin should be offered as a treatment option for the treatment of spasticity in adults and children (Level A).

View details for Web of Science ID 000256707100009

View details for PubMedID 18458229